The United Kingdom and the United States have concluded a major bilateral deal that will ensure no duties on UK pharmaceutical products entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge ensures that duties on these vital products will stay at zero for a timeframe of 36 months.
This deal is in response to recent statements to dramatically increase duties on branded pharmaceutical imports, with figures mentioned up to double the cost.
"This deal with the United Kingdom reinforces the global environment for innovative medicines and introduces much-needed balance to U.S.–U.K. drug exports," a release noted.
Trade Importance
Pharmaceuticals constitute one of the UK's biggest exports to the US, which is easily the largest destination for leading companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to last September, the UK exported medicines worth £11.1bn to the US. This value represented nearly one-fifth of total UK exports in that span.
"This guarantee safeguards work, stimulates funding and facilitates the UK to become a global hub for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The deal involves several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The sum drug companies must refund to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments were more than 20%.
Recent Tensions
This agreement comes amid a long-running tension between the pharmaceutical industry and the ministers over drug pricing and approval rates.
This friction were heightened by assertions that US customers were charged several times more for the identical medicines than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been announced toward American operations.
The Science Minister stated that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.
